CTLA4 and neoplasm: The model was further validated by the relative concordance of the simulated cancer cell decline with the tumor-killing performance of CTLA-4 blockade (compare the final population of tumor cells in anti-PD-1 and anti-CTLA-4 treatments, Figure 4c, yellow curve).